342 related articles for article (PubMed ID: 33762498)
1. [Paradoxical effect of levetiracetam on seizure suppression: three cases showing U curve association between dose and effect].
Inoue T; Kobayashi K; Usami K; Shimotake A; Inouchi M; Sakai T; Ikeda A; Takahashi R
Rinsho Shinkeigaku; 2021 Apr; 61(4):247-252. PubMed ID: 33762498
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of perampanel with concomitant levetiracetam for patients with drug-resistant epilepsy.
Kanemura H; Sano F; Aihara M
Eur J Paediatr Neurol; 2019 Jan; 23(1):197-203. PubMed ID: 30424990
[TBL] [Abstract][Full Text] [Related]
3. An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy.
Abou-Khalil B; Hemdal P; Privitera MD
Seizure; 2003 Apr; 12(3):141-9. PubMed ID: 12651078
[TBL] [Abstract][Full Text] [Related]
4. Paradoxical effects of levetiracetam in people with epilepsy with rhythmic epileptiform discharges.
Takebayashi Y; Neshige S; Shishido T; Hayashi Y; Segawa A; Nakamori M; Nezu T; Aoki S; Yamazaki Y; Ueno H; Ohshita T; Iida K; Maruyama H
Epilepsy Behav; 2023 Jun; 143():109225. PubMed ID: 37130461
[TBL] [Abstract][Full Text] [Related]
5. Levetiracetam-Associated Psychogenic Non-epileptic Seizures; A Hidden Paradox.
Jabeen SA; Gaddamanugu P; Cherian A; Mridula KM; Kumar DU; Meena AK
J Popul Ther Clin Pharmacol; 2018 Jul; 25(2):e1-e11. PubMed ID: 30725538
[TBL] [Abstract][Full Text] [Related]
6. The effect of serum levetiracetam concentrations on therapeutic response and IL1-beta concentration in patients with epilepsy.
Gulcebi MI; Kendirli T; Turgan ZA; Patsalos PN; Onat Yilmaz F
Epilepsy Res; 2018 Dec; 148():17-22. PubMed ID: 30326332
[TBL] [Abstract][Full Text] [Related]
7. An interaction study of Ocimum sanctum L. and levetiracetam in pentylenetetrazole kindling model of epilepsy.
Sarangi SC; Pattnaik SS; Katyal J; Kaleekal T; Dinda AK
J Ethnopharmacol; 2020 Mar; 249():112389. PubMed ID: 31739106
[TBL] [Abstract][Full Text] [Related]
8. Levetiracetam-Induced Seizure Aggravation in Patients With Focal Cortical Dysplasia.
Cvetkovska E; Kuzmanovski I; Babunovska M; Boshkovski B; Aleksovska K; Trencevska GK
Clin Neuropharmacol; 2018; 41(6):218-221. PubMed ID: 30234559
[TBL] [Abstract][Full Text] [Related]
9. Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group.
Maschio M; Zarabla A; Maialetti A; Fabi A; Vidiri A; Villani V; Giannarelli D
Epilepsy Behav; 2017 Aug; 73():83-89. PubMed ID: 28623754
[TBL] [Abstract][Full Text] [Related]
10. A randomized, open-label, multicenter comparative trial of levetiracetam and topiramate as adjunctive treatment for patients with focal epilepsy in Korea.
Lee SK; Lee SA; Kim DW; Loesch C; Pelgrims B; Osakabe T; Lee B;
Epilepsy Behav; 2019 Aug; 97():67-74. PubMed ID: 31195326
[TBL] [Abstract][Full Text] [Related]
11. Long-lasting antiepileptic effects of levetiracetam against epileptic seizures in the spontaneously epileptic rat (SER): differentiation of levetiracetam from conventional antiepileptic drugs.
Ji-qun C; Ishihara K; Nagayama T; Serikawa T; Sasa M
Epilepsia; 2005 Sep; 46(9):1362-70. PubMed ID: 16146430
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of levetiracetam for neonatal seizures in preterm infants.
Han JY; Moon CJ; Youn YA; Sung IK; Lee IG
BMC Pediatr; 2018 Apr; 18(1):131. PubMed ID: 29636029
[TBL] [Abstract][Full Text] [Related]
13. Correlation of levetiracetam concentration in peripheral blood mononuclear cells with clinical efficacy: A sensitive monitoring biomarker in patients with epilepsy.
Harby SA; Nassra RA; Mekky JF; Ali SM; Ismail CA
Seizure; 2020 May; 78():71-77. PubMed ID: 32213443
[TBL] [Abstract][Full Text] [Related]
14. Is the anticonvulsant activity of levetiracetam dose-dependent?
Lamouret V; Kurth C; Intravooth T; Steinhoff BJ
Seizure; 2020 Dec; 83():197-202. PubMed ID: 33197757
[TBL] [Abstract][Full Text] [Related]
15. Levetiracetam optimal dose-finding as first-line treatment for neonatal seizures occurring in the context of hypoxic-ischaemic encephalopathy (LEVNEONAT-1): study protocol of a phase II trial.
Favrais G; Ursino M; Mouchel C; Boivin E; Jullien V; Zohar S; Saliba E
BMJ Open; 2019 Jan; 9(1):e022739. PubMed ID: 30679288
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy.
Ben-Menachem E; Gilland E
Seizure; 2003 Apr; 12(3):131-5. PubMed ID: 12651076
[TBL] [Abstract][Full Text] [Related]
17. Serum levetiracetam concentrations after transdermal levetiracetam administration, 3 times daily, to healthy cats.
Smith C; Barnes Heller HL; Reif N; Van Hesteren M; Reinhart JM
J Vet Intern Med; 2019 Mar; 33(2):827-830. PubMed ID: 30663797
[TBL] [Abstract][Full Text] [Related]
18. A Rare Case of Levetiracetam and Drug-Induced Idiopathic Aseptic Meningitis in a Pediatric Patient.
McDonald D; Sultan R; Viswanathan A; Siu A
Pharmacotherapy; 2019 Jan; 39(1):109-113. PubMed ID: 30488976
[TBL] [Abstract][Full Text] [Related]
19. Eslicarbazepine acetate as a replacement for levetiracetam in people with epilepsy developing behavioral adverse events.
Jalihal V; Shankar R; Henley W; Parrett M; Tittensor P; McLean BN; Ahmed A; Sander JW
Epilepsy Behav; 2018 Mar; 80():365-369. PubMed ID: 29415871
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and Pharmacodynamic Evaluation of Intravenous Levetiracetam in Children With Epilepsy.
Kim MJ; Yum MS; Yeh HR; Ko TS; Lim HS
J Clin Pharmacol; 2018 Dec; 58(12):1586-1596. PubMed ID: 30052270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
